First patient treated with CRISPR medicine in phase 1/2 trial

The first patient has been treated in a phase 1/2 trial of AGN-151587, the first in vivo CRISPR medicine to be administered in patients, according to a press release from Editas Medicine.

The BRILLIANCE clinical trial is evaluating AGN-151587 (EDIT-101), an experimental CRISPR-based medicine administered via subretinal injection, in patients with Leber congenital amaurosis 10 (LCA10). It is the first gene editing medicine to be evaluated inside the body.

“This dosing is a truly historic event — for science, for medicine and most importantly for people living with this eye disease,” Cynthia Collins, president and CEO of Editas Medicine, said in the release. “The first patient dosed in the BRILLIANCE clinical trial marks a significant milestone toward delivering on the promise and potential of CRISPR medicines to durably treat devastating diseases such as LCA10. We look forward to sharing future updates from this clinical trial and our ocular program.”

The treatment is being developed through an alliance between Allergan and Editas Medicine in which Allergan received exclusive access and the option to license up to five of Editas Medicine’s genome editing programs for ocular diseases.

“Currently patients living with LCA10 have no approved treatment options. For years, Allergan has had an unwavering commitment to advancing eye care treatments. With the first patient treated in this historic clinical trial, we mark a significant step in advancing the AGN-151587 clinical program and move closer to our goal of developing a game-changing medicine for LCA10 patients,” Brent Saunders, chairman and CEO of Allergan, said in the release.

The first patient in the trial was treated at Oregon Health & Science University’s Casey Eye Institute.

The first patient has been treated in a phase 1/2 trial of AGN-151587, the first in vivo CRISPR medicine to be administered in patients, according to a press release from Editas Medicine.

The BRILLIANCE clinical trial is evaluating AGN-151587 (EDIT-101), an experimental CRISPR-based medicine administered via subretinal injection, in patients with Leber congenital amaurosis 10 (LCA10). It is the first gene editing medicine to be evaluated inside the body.

“This dosing is a truly historic event — for science, for medicine and most importantly for people living with this eye disease,” Cynthia Collins, president and CEO of Editas Medicine, said in the release. “The first patient dosed in the BRILLIANCE clinical trial marks a significant milestone toward delivering on the promise and potential of CRISPR medicines to durably treat devastating diseases such as LCA10. We look forward to sharing future updates from this clinical trial and our ocular program.”

The treatment is being developed through an alliance between Allergan and Editas Medicine in which Allergan received exclusive access and the option to license up to five of Editas Medicine’s genome editing programs for ocular diseases.

“Currently patients living with LCA10 have no approved treatment options. For years, Allergan has had an unwavering commitment to advancing eye care treatments. With the first patient treated in this historic clinical trial, we mark a significant step in advancing the AGN-151587 clinical program and move closer to our goal of developing a game-changing medicine for LCA10 patients,” Brent Saunders, chairman and CEO of Allergan, said in the release.

The first patient in the trial was treated at Oregon Health & Science University’s Casey Eye Institute.